Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 629 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: quinolone Clear all

Conditions: Pseudomonas Infection
Interventions: Ciprofloxacin (Cipro, BAYQ3939); Drug
Lead sponsor: Bayer; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Hyperuricemia, Gout, Qt Interval, Variation in
Interventions: LC350189 200mg, Placebo, Moxifloxacin 400mg, LC350189 600mg; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Alcohol Dependence
Interventions: aripiprazole (up to 15 mg/day) for 8 days; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Interventions: Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine; Drug
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 20
States / cities: La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more

Conditions: Pharmacokinetics
Interventions: monophasic oral contraceptive, AZD7325; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Community Acquired Pneumonia
Interventions: lefamulin, Moxifloxacin, Linezolid; Drug
Lead sponsor: Nabriva Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 7
States / cities: Hazard, Kentucky • Shreveport, Louisiana • Minneapolis, Minnesota + 4 more

Conditions: Healthy Volunteers
Interventions: Methylnaltrexone (MNTX), Placebo, Moxifloxacin; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 546 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Schizophrenia
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Wallingford, Connecticut

Conditions: Dysbacteriosis
Interventions: Ciprofloxacin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bacterial Resistance
Interventions: Ciprofloxacin, Standard Aseptic Technique; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Schizophrenia
Interventions: Olanzapine, Aripiprazole; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 24
States / cities: Little Rock, Arkansas • Garden Grove, California • National City, California + 21 more

Conditions: Corneal Ulcers
Interventions: Besivance 0.6% Ophthalmic Suspension, Zymaxid 0.5% Ophthalmic Solution, Vigamox 0.5% Ophthalmic Solution; Drug
Lead sponsor: Cornea Consultants Of Nashville; Other
Eligibility: 18 Years to 90 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Healthy Volunteers
Interventions: AKB-6548 (therapeutic dose), AKB-6548 (supratherapeutic dose), Placebo, Moxifloxacin; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Contraception Behavior
Interventions: Ethinyl Estradiol / Norgestimate Oral Tablet; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 14 Years to 23 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Systemic Lupus Erythematosus, Healthy Participants
Interventions: BMS-986165, Moxifloxacin, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: HIV Infections
Interventions: Atazanavir+Ritonavir+Tenofovir, Atazanavir+Ritonavir+Tenofovir+Famotidine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Hamilton, New Jersey

Conditions: Bacterial Infections, Eye Infections
Interventions: AzaSite (azithromycin ophthalmic solution), Vigamox (moxifloxacin hydrochloride ophthalmic solution); Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: CHF 4226 pMDI, Placebo, Moxifloxacin; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Community Acquired Pneumonia in Children
Interventions: Ampicillin for Injection, Ceftriaxone for Injection, Amoxicillin, Ampicillin / Sulbactam Injection, Amoxicillin-clavulanate, Clindamycin, Cefprozil, Levofloxacin; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 3 Months to 18 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Insulin Sensitivity, Cardiovascular Risk, Perimenopausal Disorder
Interventions: Ortho Cyclen®; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions: Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 598 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Sylmar, California • Royal Oak, Michigan • Lima, Ohio

Conditions: Osteomyelitis
Interventions: oral antibiotics, intravenous antibiotics; Drug · Procedure
Lead sponsor: Julio Ramirez; Other
Eligibility: 18 Years to 100 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Amount of NKTR-118 in Blood, Variation in the Heart's Electrical Cycle
Interventions: NKTR-118, moxifloxacin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Cancer
Interventions: 68Ga-FAPI, Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan; Drug · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 19 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.

Cipro Inhaler for Cystic Fibrosis Children Ages 6-12

Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects

Aripiprazole Effects on Alcohol Reactivity and Consumption

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Determine the Effects of C-administration of AZD7325 and an Oral Contraceptive in Healthy Female Subjects

Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia

Effect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac Repolarization

Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia

Longitudinal Study of the Human Intestinal Microbiome

Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics

Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia

A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.

Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers

Premature Discontinuation of Contraceptive Implants

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects

Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir

Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers

Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers

Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP

Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

Patients Response to Early Switch To Oral:Osteomyelitis Study

A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects

68-Ga-FAPI PET Imaging in Malignancy